Barclays Lifts Fortrea (FTRE) PT to $8 Amid Q3 2025 Life Sciences Preview

Fortrea Holdings Inc. (NASDAQ:FTRE) is one of the cheap stocks to buy for the next 5 years. On October 2, Barclays raised the firm’s price target on Fortrea to $8 from $6, while keeping an Underweight rating as part of a Q3 2025 preview for the life science tools and diagnostics group. Earlier in Q2, Fortrea Holdings made a quarterly revenue of $710.3 million, which was up 7.23% year-over-year.

The company also achieved an Adjusted EBITDA of $54.9 million and an adjusted net income per diluted share of $0.19, which led management to raise its full-year 2025 revenue guidance to a range of $2.6 to $2.7 billion, while affirming its Adjusted EBITDA guidance.

But despite this growth, Fortrea recorded a GAAP net loss of $374.9 million, or $4.14 per diluted share due to a substantial non-cash goodwill impairment charge of $309.1 million. Fortrea’s backlog stood at $7.547 billion. In Q2, the company affirmed that its cost-saving initiatives remain on track.

Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization that provides biopharmaceutical product & medical device development solutions to pharmaceutical, biotechnology, and medical device customers.

While we acknowledge the potential of FTRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.